Cipla gets nod to raise funds upto Rs 3000 crore via NCDs

22 May 2019 Evaluate

Cipla has received an approval to raise funds upto Rs 3000 crore by issue of non-convertible debentures (NCDs) (in form of bonds or otherwise) or bonds, whether denominated in Indian Rupee and/or foreign currency (ies), though a public issue or a private placement in accordance with the provisions of the applicable law. The Board of directors of the company at its meeting held on May 22, 2019 has approved for the same.

The company’s board also approved raising funds upto Rs 3000 crore by issue of equity shares or American depository receipts or global depository receipts or foreign currency convertible bonds or other securities/financial instruments convertible into equity shares, whether denominated in Indian Rupee and/or foreign currency (ies), though a public issue or a private placement in accordance with the provisions of the applicable law.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1406.25 0.85 (0.06%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.